Viewpoints » Visby Connects with City and County Health Officials at NACCHO in Atlanta

07/05/2022 • Viewpoint

Visby Connects with City and County Health Officials at NACCHO in Atlanta

Visby brings point-of-care PCR to the deep south with an appearance at NACCHO360.

Visby Joins the NACCHO360 Conference in Atlanta, GA

July 19-June 21, 2022

Hyatt Regency Atlanta
265 Peachtree St NE
Atlanta, GA 30303

Booth: 202

During the COVID-19 pandemic, sexually transmitted infection (STI) rates have risen to all time highs. Current STI testing takes too long and often leads to presumptive treatment, causing overuse of antibiotics or under-treatment of patients.

Learn more about the world’s first hand-held, point-of-care PCR testing device, created especially so clinicians can rapidly provide data-driven treatment and start to reverse the STI epidemic — stop by booth #202 at they Hyatt Regency in Atlanta, July 18-24.

Expected attendees: 1,300

Learn more about the Visby Medical Sexual Health Test

04/05/2024 • Viewpoint

The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

In light of the rising rates of sexually transmitted infections (STIs), urgent care clinics have found themselves at a crucial crossroads. PCR (Polymerase Chain Reaction) testing at the point of care emerges as a potential game-changer.

03/14/2024 • Viewpoint

Understanding the Financial Impact of PCR Point of Care Testing for STIs

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

03/07/2024 • Viewpoint

5 Frequently Asked Questions on Implementing PCR into Urgent Care

02/21/2024 • Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.